Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests

Table 1 FP and FN rates for immunohistochemical testing as recorded by the NordiQC programme

	Approved IVD, n (%) (n = 1145)		Laboratory-developed IVD, n (%) (n = 558)
Data source	FN	FP	FN	FP
NordiQC runs B6–14^a	127 (11)	0	141 (25)	28 (5)

FN false negative, FP false positive, IVD in vitro diagnostic, NordiQC Nordic Immunohistochemistry Quality Control Group
^aNordiQC IHC quality-control organisation, B6–14 runs [15]. Laboratories were provided with samples that were IHC 0, 1+, 2+ and 3+

ISSN: 1472-6963